About Sensible Biotechnologies
Sensible Biotechnologies is a company based in Wilmington (United States) founded in 2021 by Miroslav Gasparek. Sensible Biotechnologies has raised $4.33 million across 2 funding rounds from investors including BlueYard Capital, Y Combinator and Amino Collective. Sensible Biotechnologies offers products and services including mRNA Manufacturing Platform and In Vivo Microbial mRNA System. Sensible Biotechnologies operates in a competitive market with competitors including Twist Bioscience, Parse Biosciences, Ansa Biotechnologies, Sino Biological and GenScript, among others.
- Headquarter Wilmington, United States
- Founders Miroslav Gasparek
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Sensible Biotechnologies, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$4.33 M (USD)
in 2 rounds
-
Latest Funding Round
$4.2 M (USD), Seed
Feb 21, 2023
-
Investors
BlueYard Capital
& 7 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Sensible Biotechnologies
Sensible Biotechnologies offers a comprehensive portfolio of products and services, including mRNA Manufacturing Platform and In Vivo Microbial mRNA System.
Produces pure mRNA for therapeutics and vaccines efficiently.
Enables scalable mRNA production for global health applications.
Funding Insights of Sensible Biotechnologies
Sensible Biotechnologies has successfully raised a total of $4.33M across 2 strategic funding rounds. The most recent funding activity was a Seed round of $4.2 million completed in February 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Sensible Biotechnologies
Sensible Biotechnologies has secured backing from 8 investors, including venture fund and angel investors. Prominent investors backing the company include BlueYard Capital, Y Combinator and Amino Collective.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
BlueYard Capital is engaged in early-stage technology investments.
|
Locked | Locked | Locked | |
|
Early-stage startups are accelerated via funding and educational programs.
|
Locked | Locked | Locked | |
|
Amino Collective is engaged in backing innovative startup founders.
|
Locked | Locked | Locked |
Investor details for Sensible Biotechnologies
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Sensible Biotechnologies
Investment portfolio details for Sensible Biotechnologies
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Sensible Biotechnologies
Detailed financials for Sensible Biotechnologies
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Sensible Biotechnologies Comparisons
Peer comparison for Sensible Biotechnologies
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Sensible Biotechnologies
Sensible Biotechnologies operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Twist Bioscience, Parse Biosciences, Ansa Biotechnologies, Sino Biological and GenScript, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Synthetic DNA is synthesized via a semiconductor-based platform.
|
|
| Locked | Locked | Locked |
RNA-sequencing transcriptome kits for health data analysis are developed.
|
|
| Locked | Locked | Locked |
DNA synthesis technology using enzymes is provided.
|
|
| Locked | Locked | Locked |
Reagents and kits are provided for clinical research applications.
|
|
| Locked | Locked | Locked |
Reagents and instruments are provided for life sciences research.
|
|
| Locked | Locked | Locked |
Develops tools and products for research and clinical application
|
Detailed competitors of Sensible Biotechnologies
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Sensible Biotechnologies
Complete news archive for Sensible Biotechnologies
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Sensible Biotechnologies
Sensible Biotechnologies was founded in 2021.
Sensible Biotechnologies is headquartered in Wilmington, United States. It is registered at Wilmington, Delaware, United States.
Miroslav Gasparek is the current CEO of Sensible Biotechnologies. They have also founded this company.
Sensible Biotechnologies is a funded company, having raised a total of $4.33M across 2 funding rounds to date.
Sensible Biotechnologies was founded in 2021 and is headquartered in Wilmington, United States. Focus is placed on the biotechnology sector, where mRNA technology is designed and manufactured for therapeutics and vaccines. Principles of cell engineering, computational biology, and precision fermentation are integrated into operations to enable efficient production. Leadership is provided by co-founder and CEO Miroslav Gasparek, with activities centered on advancing mRNA applications in healthcare.
Sensible Biotechnologies's top competitors include Sino Biological, Parse Biosciences and GenScript.
Sensible Biotechnologies offers mRNA Manufacturing Platform and In Vivo Microbial mRNA System.
Sensible Biotechnologies has 8 investors. Key investors include BlueYard Capital, Y Combinator, Amino Collective, Civilization Ventures, and Recode Ventures.